KROS - Keros Therapeutics, Inc.
Dimensional Fund Advisors LP lifted its holdings in Keros Therapeutics, Inc. (NASDAQ: KROS) by 453.9% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 321,360 shares of the company's stock after buying an additional 263,347 shares during
Empowered Funds LLC raised its holdings in Keros Therapeutics, Inc. (NASDAQ: KROS) by 142.2% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 145,517 shares of the company's stock after purchasing an additional 85,439 shares during the period. Empowered
Keros posts a wider Q2 loss as revenues fall to zero, while cash runway into H1 2028 and rinvatercept pipeline milestones keep attention on future growth.
LEXINGTON, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the quarter ended June 30, 2026.
LEXINGTON, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it will receive a $20 million development milestone payment under the terms of the license agreement of elritercept with partner Takeda, following the dosing of the first patient in the ELRiSE MDS clinical trial. ELRiSE MDS is a Phase 3, multicenter, open-label, randomized trial to compare the efficacy and safety of elritercept versus epoetin alfa for the treatment of anemia due to very low, low, or intermediate risk myelodysplastic syndromes (“MDS”).
ITRG, BEEM and KROS have been added to the Zacks Rank #5 (Strong Sell) List on July 30, 2026.
LEXINGTON, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced the appointment of Anne Prener, M.D., Ph.D., to its Board of Directors, effective July 1, 2026.
Keros Therapeutics, Inc. (KROS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
LEXINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros' President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 4:00 p.m. Eastern time.
Keros faces a volatile setup after its Q1 miss, with a longer cash runway and leaner costs balanced against uncertain milestone-driven revenue.
Keros is shifting toward rinvatercept-led neuromuscular development, with phase II plans, early human signals and cash runway shaping the KROS story.
Keros heads into 2026 with rinvatercept catalysts in DMD and ALS as investors watch phase II plans, orphan status and early clinical signals.
KROS posts a wider Q1 loss as revenues fall due to the absence of license revenues. The company advances rinvatercept and elritercept studies.
Keros Therapeutics, Inc. (KROS) came out with a quarterly loss of $1.21 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to earnings of $3.62 per share a year ago.
LEXINGTON, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today reported financial results for the quarter ended March 31, 2026.
Keros heads into 2026 with three key catalysts, including DMD study start, ALS regulatory talks, and Takeda progress, that could reshape investor sentiment.
Keros Therapeutics KROS reshaped its financial profile in 2025 by pairing a major licensing transaction with a shift in development responsibilities. The result was a step-change in reported revenue and a meaningful reduction in internal research and development burden.
KROS sharpens focus on rinvatercept as a phase II DMD study looms in 2026, shifting the story toward execution and high-stakes clinical catalysts.
JPMorgan Chase and Co. grew its position in shares of Keros Therapeutics, Inc. (NASDAQ: KROS) by 260.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 171,941 shares of the company's stock after buying an additional 124,287 shares during the
Keros Therapeutics (KROS) reported earnings 30 days ago. What's next for the stock?